Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma

相似書籍

• Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient
  由: Kovacs, Sarolta Bojtine, et al.
  出版: (2020)
• Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
  由: Shoumariyeh, Khalid, et al.
  出版: (2021)
• Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
  由: Greil, Christine, et al.
  出版: (2019)
• The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
  由: Paiva, Bruno, et al.
  出版: (2015)
• Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)
  由: Waldschmidt, Johannes M., et al.
  出版: (2018)